SecBot SecBot
424B5 ·Filed Nov 5, 2026

ZBH

ZIMMER BIOMET HOLDINGS, INC.
NEUTRAL
Impact 2/10
Horizonweeks Processed11d 20h ago SEC0001193125-26-448356
Notable filing: 424B5
Actionable Insight • Neutral

Monitor the final pricing supplement for the definitive offering size, coupon, and maturity. The proximity to earnings and the stated intent to refinance near-term maturities suggest a liability management exercise rather than new leverage. The EUR 500M 2.425% notes mature December 13, 2026 and the $600M 4.700% notes mature February 19, 2027, creating a refinancing catalyst in the coming months.

DirectionNeutral
Confidencemedium
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$106.85
T+0 close · Nov 5, 2026 · via day close
Latest settled
−2.14%
T+5 · $104.56
Vs SPY
−5.43%
α at T+5
Next horizon
T+20
in 17d
  1. T+0 · Nov 5 $106.85entry
  2. T+1 · 11d ago −1.18%α −1.49% · $105.59
  3. T+5 · 5d ago −2.14%α −5.43% · $104.56
  4. T+7 · todayOpen
  5. T+20 · in 17d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Zimmer Biomet filed a preliminary 424B5 prospectus supplement for an underwritten offering of euro-denominated senior unsecured notes. The offering size, interest rate, maturity, and pricing are all placeholder TBD values, making this a preliminary filing with no definitive terms. Proceeds are intended for general corporate purposes including potential repayment of EUR 500M 2.425% notes due December 2026 and/or $600M 4.700% notes due February 2027. The filing follows the company's Q3 2026 earnings release on November 4, 2026, which showed modest revenue growth and raised guidance.

Key Financial Metrics

Underwriters
Barclays Bank PLC, Citigroup Global Markets Limited +3

Key Facts

  • Preliminary prospectus supplement for an underwritten offering of senior unsecured notes denominated in euro
  • Offering size, interest rate, maturity, and pricing are all placeholder values (TBD)
  • Proceeds intended for general corporate purposes including potential repayment of EUR 500M 2.425% notes due December 2026 and/or $600M 4.700% notes due February 2027
  • Joint book-running managers: Barclays, Citigroup, HSBC, Morgan Stanley, RBC Capital Markets
  • Company had approximately $7.5 billion of indebtedness outstanding as of September 30, 2026
  • Filed one day after Q3 2026 earnings (8-K on November 4, 2026) which reported net sales of $2.063B (+3.1% reported) and raised full-year guidance

Financial Impact

Undisclosed amount; proceeds will be used for general corporate purposes including potential refinancing of EUR 500M and $600M notes maturing in late 2026 and early 2027

debtinterest expense

Risk Factors

  • Preliminary filing with no definitive terms; actual offering size, pricing, and structure may differ
  • Adding new debt increases total leverage and interest expense
  • Euro-denominated notes introduce foreign exchange risk for U.S.-based investors
  • document contains text addressed to automated readers

Market Snapshot

Exchange
NYSE
Sector
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Analyst Consensus
32% bullish (31 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
424B5 Filing (Primary)0001193125-26-448356
Document: 0001193125-26-448356-index-headers.html0001193125-26-448356
Document: 0001193125-26-448356-index.html0001193125-26-448356
Document: 0001193125-26-448356.txt0001193125-26-448356

Track record

17 reports on ZBH

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +8.74% at T+60 after the Apr 28, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Neutral 3/10 Entry $103.21 Now $101.41 −1.74% settles Nov 20
  2. Nov 9, 20267d ago 424B5 Neutral 3/10 Entry $107.32 Now $101.41 −5.51% settles Nov 17
  3. Nov 9, 20267d ago 424B5 Neutral 3/10 Entry $107.32 Now $101.41 −5.51% settles Nov 17
  4. Nov 5, 202611d ago 424B5 Neutral 3/10 Entry $106.85 to $104.56 Now $101.41 −5.09% ▼ −2.14% −5.43% vs SPY
  5. Nov 5, 202611d ago 424B5 Neutral 2/10 Viewing Entry $106.85 to $104.56 Now $101.41 −5.09% ▼ −2.14% −5.43% vs SPY
  6. Nov 4, 202612d ago 8-K Neutral 5/10 Entry $110.15 to $107.47 Now $101.41 −7.93% ▼ −2.43% −1.52% vs SPY
  7. Oct 26, 202621d ago Institutional Cluster Bearish 4/10 Entry $97.44 to $94.52 Now $101.41 −4.07% ▲ +3.00% +1.74% vs SPY
  8. Oct 21, 202627d ago Court Ruling Bearish 6/10 Entry $98.81 to $97.47 Now $101.41 −2.63% ▲ +1.36% +2.06% vs SPY
  9. Sep 15, 20268w ago Insider Cluster Neutral 3/10 Entry $96.53 to $90.64 Now $101.41 +5.06% ▼ −6.10% −8.17% vs SPY
  10. Sep 2, 202610w ago Court Ruling Neutral 2/10 Entry $98.66 to $93.24 Now $101.41 +2.79% ▼ −5.49% −4.34% vs SPY
Showing 10 of 17

US Market Status

Market Closed · Opens in 6h 55m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026